NCT00510354已完成4 期
Multicenter, Single-arm, Two Stage Phase II Trial of RAD001 (Everolimus) With Imatinib in Imatinib-resistant Patients With Progressive GIST
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).
研究概览
简要总结
The purpose of this multicenter, single-arm, Simon two-stage, phase II trial is to determine the efficacy and safety of everolimus in combination with Imatinib mesylate in patients with previously treated, histologically proven GIST whose disease has recurred or progressed while receiving 400 mg/day of Imatinib mesylate at any time during at least a 2 months' treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
RAD001 + Imatinib
Experimental
干预措施: Imatinib mesylate (Drug)
结局指标
主要结局
Tumor assessments should be performed by a CT or MRI scan after 4 months. Response to treatment with RAD001 plus Imatinib mesylate at 4 months (defined as progression-free survival (PFS) at 4 months).
时间窗: at 4 months
次要结局
- Tolerability and safety assessed by AEs and SAEs. Objective tumor response rate (complete response [CR] and partial response [PR]) assessed by CT or MRI PFS at month 12 for patients with data available from follow up observation (optional)(At 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaAdenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionHER2-positive Gastric CancerNCT05715931Yu jiren30
招募中
2 期
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Primary Central Nervous System LymphomaNCT05549284Affiliated Hospital to Academy of Military Medical Sciences36
已完成
2 期
Treatment of Patients With RAD001 With Progressive SarcomaProgressive SarcomaNCT00767819Novartis Pharmaceuticals71
已完成
2 期
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell LymphomaDiffuse Large B Cell LymphomaNCT04214626Henan Cancer Hospital60
进行中（未招募）
2 期
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Non-Small Cell Lung CancerNCT06606847AstraZeneca30